Developing a DARTS proteomics method to identify the host-based targets of KSHV lytic replication inhibitors

Kaposi sarcoma-associated herpesvirus (KSHV) is virus, whose unabated lifecycle results in the formation of cancerous tumorous. Moreover, KSHV infection is particularly prevalent in people living with HIV, and has a disproportionate burden in sub-Saharan Africa. Despite this clear unmet medical need, there are no approved treatments for KSHV. Recent work, conducted in South Africa has identified a drug-like compound, with encouraging anti-KSHV properties. However, we do not fully understand how this drug-like compound is able to exert its effect, which is hampering our ability to translate these findings into a tangible therapeutic strategy. In this project we aim to combine the significant proteomics expertise house at the University of Victoria, with our substantial experience in drug discovery, to resolve this outstanding problem.
The combined skills are complimentary, and as such this project will allow for two-ways skills transfer, which can be applied in future projects, both in South Africa and Canada in the wider drug discovery space. Furthermore, this will catalyze a longer terms collaborative environment between the listed researchers

Faculty Supervisor:

David Goodlett

Student:

Partner:

University of Cape Town

Discipline:

Physics

Sector:

Pharmaceuticals; Health and Related Sciences & Technology

University:

University of Victoria

Program: